adenine has been researched along with didanosine in 110 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (5.45) | 18.2507 |
2000's | 93 (84.55) | 29.6817 |
2010's | 11 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Balzarini, J; Bergamini, A; Calio, R; De Clercq, E; Milanese, G; Pauwels, R; Perno, CF; Rocchi, G; Yarchoan, R | 1 |
Broder, S; Kageyama, S; Mitsuya, H; Yarchoan, R | 1 |
Ahmed, PS; Brennan, TM; Bridges, CG; Casara, P; Hornsperger, JM; Navé, JF; Taylor, DL; Tyms, AS | 1 |
Anderson, BD; Ho, NF; Singhal, D | 1 |
Merigan, TC; Palmer, S; Shafer, RW | 1 |
Crabbs, C; Greenhouse, J; Lewis, MG; Lisziewicz, J; Lori, F; Silvera, P; Tinelli, C; Varga, G; Wagner, W; Xu, J; Yalley-Ogunro, J; Zinn, DE | 1 |
Cheng, B | 1 |
Birkus, G; Cihlar, T; Greenwalt, DE; Hitchcock, MJ | 1 |
Coull, JJ; Drusano, GL; Hossain, MM; Margolis, DM | 1 |
Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
Chou, S; Murphy, MD; O'Hearn, M | 1 |
Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
Fridland, A; Robbins, BL; Rodman, JH; Wilcox, CK | 1 |
Callens, S; Colebunders, R; De Schacht, C; Huyst, V | 1 |
Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R | 1 |
Kirian, MA; Pecora Fulco, P | 1 |
Blanchard, JN; Canas, A; King, K; Lonergan, JT; Wohlfeiler, M | 1 |
Abad, S; Blanche, P; Chauvelot-Moachon, L; Daniel, N; Kélaïdi, C; Nazal, EM; Rollot, F; Saba, M | 1 |
Cunningham, CK; McKinney, RE | 1 |
Boyle, BA | 1 |
Fridland, A; Olson, L; Ray, AS | 1 |
Carter, M | 1 |
Gazzard, B; Mandalia, S; Nelson, M; Pillay, D; Pozniak, A; Winston, A | 1 |
Barrios, A; García-Benayas, T; González-Lahoz, J; Soriano, V | 1 |
Burger, D; Clotet, B; Grassi, J; Juan, M; Masmitjà, E; Moltó, J; Negredo, E; Paredes, R; Pruvost, A; Puig, J; Ribera, E; Ruiz, L; Viciana, P | 1 |
Gutiérrez, F; Masiá, M; Padilla, S; Pascual, J; Ramos, JM | 2 |
Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S | 1 |
Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
Fung, HB; Guo, Y | 1 |
Fulco, PP; Higginson, RT; Kirian, MA | 1 |
Aguero, J; Corral, A; de Mendoza, C; Gallego, O; Martin-Carbonero, L; Soriano, V | 1 |
Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
Boeri, E; Castagna, A; Clementi, M; Fusetti, G; Galli, A; Gianotti, N; Lazzarin, A; Salpietro, S; Seminari, E | 1 |
Anderson, PL; Becker, SL; Kakuda, TN | 1 |
Blanco, JL; Gatell, JM; Laguno, M; León, A; Mallolas, J; Martinez, E; Pumarola, T | 1 |
Sax, PE | 1 |
Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
Barreiro, P; Barrios, A; Blanco, F; Clotet, B; Cooper, D; Domingo, P; Garcia-Benayas, T; Gil, P; Gonzalez-Lahoz, J; Labarga, P; Maida, I; Martín-Carbonero, L; Negredo, E; Núñez, M; Rendón, A; Sambeat, MA; Sánchez-Conde, M; Santos, J; Soriano, V | 1 |
Abraira, V; Antela, A; Casado, JL; Dronda, F; Gutiérrez, C; López, D; Moreno, A; Moreno, S; Pérez-Elías, MJ; Rodríguez, MA | 1 |
Benech, H; Clotet, B; García, E; Grassi, J; Grau, E; Moltó, J; Negredo, E; Pruvost, A; Puig, J; Theodoro, F | 1 |
Margot, NA; Miller, MD | 1 |
Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Tung, MY | 1 |
Girard, PM; Lacombe, K; Meynard, JL; Pacanowski, J; Trylesinski, A | 1 |
Boffito, M; Gazzard, B; Hand, J; Maitland, D; Mandalia, S; Moyle, G; Nelson, M | 1 |
Bonjoch, A; Clotet, B; Negredo, E; Paredes, R; Puig, J | 1 |
Maitland, D; Moyle, GJ; Waters, L | 1 |
Biglia, A; Blanco, JL; De Lazzari, E; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Milincovic, A; Pumarola, T | 1 |
Battegay, M; Cavassini, M; Elzi, L; Furrer, H; Gayet-Ageron, A; Hirschel, B; Karrer, U; Ledergerber, B; Russotti, M; Schmid, P; Speck, RF; Weber, R | 1 |
Chen, SS; Cheng, AK; Flaherty, JF; Kaul, S; Kearney, BP; Sayre, JR | 1 |
Asensi, V; Barrios, A; Clotet, B; Domingo, P; Estrada, V; Labarga, P; Morales, D; Negredo, E; Santos, J; Soriano, V | 1 |
Diaz, RS | 1 |
Cardellach, F; Casademont, J; Clotet, B; Garrabou, G; Infante, AB; López, S; Miró, O; Negredo, E; Puig, J; Ramos, X; Ruiz, L; Sanjurjo, E | 1 |
Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
Côté, HC; Gadawski, I; Harrigan, PR; Harris, M; Hogg, R; Magil, AB; Montaner, JS; Scarth, BJ; Wang, N; Werb, R; Yip, B; Yu, E; Zalunardo, N | 1 |
Barreiro, P; Soriano, V | 1 |
Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
Armon, C; Baker, RK; Holmberg, SD; Moorman, AC; Weidle, PJ; Wood, KC; Young, B | 1 |
Barreiro, P; Barrios, A; Blanco, F; García-Benayas, T; González-Lahoz, J; Maida, I; Rendón, AL; Rivas, P; Rodríguez-Novóa, S; Soriano, V | 1 |
Bacheler, L; Koontz, D; Mellors, JW; Parikh, UM | 1 |
Anderson, PL; Kakuda, TN | 1 |
Amiel, C; Guessant, S; Kara, A; Lebrette, MG; Marechal, Eda S; Pialoux, G; Quercia, R; Renaud, S; Schneider, V; Thevenet, S | 1 |
Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
Brenner, BG; Doualla-Bell, F; Essex, M; Frankel, F; Moisi, DD; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
Cirino, CM; Kan, VL | 1 |
Alvarez, ML; Cihlar, T; Cordobilla, B; Domingo, JC; Domingo, P; Giralt, M; Guallar, J; López-Dupla, M; Sánchez de la Rosa, R; Saumoy, M; Torres, F; Vidal, F; Villarroya, F | 1 |
Bongiovanni, M; Tordato, F | 1 |
Bogner, J; Claas, GJ; Goebel, FD; Jülg, B | 1 |
Antinori, A; Antonucci, F; Barreiro, P; Carosi, G; De Silvestri, A; El Hamad, I; Ladisa, N; Lapadula, G; Maggiolo, F; Mandalia, S; Maserati, R; Migliorino, G; Pierotti, P; Sighinolfi, L; Soriano, V; Suter, F; Torti, C | 1 |
Maggiolo, F; Ripamonti, D; Suter, F | 1 |
Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
Crane, HM; Harrington, RD; Kestenbaum, B; Kitahata, MM | 1 |
Clotet, B; Girard, PM; Negredo, E; Neubacher, D; Youle, M | 1 |
Ball, C; Hawkins, S | 1 |
Bae, AS; Borroto-Esoda, K; Goodman, D; Margot, NA; Miller, MD; Svarovskaia, ES; Waters, JM; Zhong, L | 1 |
Ainsworth, J; Booth, C; Bradshaw, D; Geretti, AM; Malik, S; Pattery, T; Van Houtte, M; Waters, A | 1 |
Burger, DM; Droste, JA; Lange, JM; Lowe, SH; Prins, JM; Reiss, P; Repping, S; van der Veen, F; van Leeuwen, E | 1 |
Abeli, C; Antinori, A; Bongiovanni, M; Capetti, A; Castagna, A; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; de Luca, A; di Biagio, A; Gatti, F; Gianotti, N; Marconi, P; Matti, A; Mussini, C; Nasta, P; Tirelli, V; Torti, C; Zaccarelli, M | 1 |
Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
Barreiro, P; Corral, A; de Mendoza, C; Garrido, C; González-Lahoz, J; Jiménez-Nacher, I; Poveda, E; Soriano, V; Zahonero, N | 1 |
Ayen, R; Bellido, R; Cardellach, F; Clotet, B; Garrabou, G; Lòpez, S; Miró, O; Morén, C; Negredo, E; Puig, J | 1 |
Borroto-Esoda, K; Feng, JY; Goodman, D; Kutty, N; Ly, JK; Margot, NA; Miller, MD; Myrick, F; Svarovskaia, ES; Wang, R; White, KL | 1 |
Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
Green, E; Hosseini, SH; Hoying-Brandt, A; Johnson, DM; Kohler, JJ; Lewis, W; Raper, CM; Russ, R; Santoianni, R; Tran, D | 1 |
Alvarez, S; Brumble, LM; Dwyer, JP; Irizarry-Alvarado, JM; Mendez, JC | 1 |
Atta, MG; Fine, DM | 1 |
Yoganathan, K | 1 |
Kirschner, J; Lebrecht, D; Venhoff, AC; Venhoff, N; Walker, UA; Wiech, T | 1 |
Beltrame, A; Bozzano, F; Cenderello, G; Costa, P; De Maria, A; Di Biagio, A; Fenoglio, D; Ferrea, G; Pagano, G | 1 |
Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
Barnas, D; Bazmi, H; Bixby, C; Jemsek, J; Koontz, D; Mellors, JW | 1 |
Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 1 |
Bénet, T; Billioud, C; Boibieux, A; Brochier, C; Chevallier, M; Cotte, L; Ferry, T; Miailhes, P; Scoazec, JY; Vanhems, P; Zoulim, F | 1 |
Babusis, D; Durand-Gasselin, L; Flaherty, JF; Hawkins, T; Ray, AS; Reddy, YS; Veikley, W | 1 |
Clauss, M; Desta, Z; Deuter-Reinhard, M; Green, L; Gupta, SK; Kim, C; Taylor, BM | 1 |
Hansen, BE; Janssen, HL; Koëter, T; Komuta, M; Rossing, HH; Schouten, JN; Van der Ende, ME; van der Valk, M; Verheij, J | 1 |
Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM | 1 |
Govender, T; Mackraj, I; Ojewole, E; Rambharose, S | 1 |
7 review(s) available for adenine and didanosine
Article | Year |
---|---|
Targeted therapy of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; CD4 Antigens; Didanosine; Dideoxynucleosides; Dipyridamole; Drug Synergism; Gene Expression Regulation, Viral; Genes, nef; Genes, rev; Genes, tat; HIV; HIV Protease; Interferon Type I; Organophosphonates; RNA-Directed DNA Polymerase; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1991 |
Effect of tenofovir on didanosine absorption in patients with HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Clinical Trials as Topic; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Peptide Fragments; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2004 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Tenofovir and didanosine: a dangerous liaison.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Tenofovir | 2005 |
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
Topics: Acidosis, Lactic; Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Liver Failure; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Antagonism; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tenofovir | 2006 |
19 trial(s) available for adenine and didanosine
Article | Year |
---|---|
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Tenofovir poses risk with didanosine.
Topics: Adenine; Anti-HIV Agents; Contraindications; Didanosine; Drug Administration Schedule; Humans; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Tenofovir | 2003 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Organophosphonates; Pancreatitis; Patient Compliance; Quality of Life; RNA, Viral; Tenofovir | 2004 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Topics: Adenine; Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Lymphopenia; Male; Organophosphonates; Retrospective Studies; Tenofovir; Virus Replication | 2005 |
High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2005 |
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Topics: Adenine; Anti-HIV Agents; Cell Count; Chromatography, Liquid; Cross-Sectional Studies; Didanosine; Half-Life; HIV Infections; HIV-1; Humans; Kinetics; Longitudinal Studies; Mass Spectrometry; Organophosphonates; Phosphorylation; Reference Standards; Tenofovir | 2005 |
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Tenofovir; Treatment Failure | 2005 |
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Tenofovir; Time Factors; Viral Load | 2005 |
Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Food-Drug Interactions; Humans; Male; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Middle Aged; Odds Ratio; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Didanosine; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Hemoglobins; HIV Infections; Humans; Lactic Acid; Male; Middle Aged; Organophosphonates; Phosphates; Skinfold Thickness; Stavudine; Tenofovir; Treatment Outcome; Triglycerides; Uric Acid; Viral Load | 2007 |
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Topics: Adenine; Alleles; Didanosine; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2007 |
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2007 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Deoxyadenine Nucleotides; Deoxyguanine Nucleotides; Didanosine; Dideoxynucleotides; Female; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2011 |
84 other study(ies) available for adenine and didanosine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; Doxorubicin; Drug Interactions; HIV; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocytes; Macrophages; Monocytes; Organ Specificity; Organophosphonates; Zalcitabine; Zidovudine | 1992 |
MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; DNA, Viral; Guanine; HIV Infections; HIV-1; HIV-2; Humans; Male; Mice; Mice, SCID; Monocytes; Organophosphonates; Spleen; T-Lymphocytes; Zidovudine | 1996 |
Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2',3'-dideoxyinosine in the mesenteric vein cannulated rat ileum.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Anti-HIV Agents; Biological Availability; Biological Transport; Catheterization; Didanosine; Enzyme Inhibitors; Ileum; Intestinal Absorption; Male; Mesenteric Veins; Pentostatin; Permeability; Prodrugs; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Rats; Rats, Sprague-Dawley | 1998 |
Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
Topics: Adenine; Anti-HIV Agents; Antineoplastic Agents; Didanosine; DNA, Viral; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Hydroxyurea; Inhibitory Concentration 50; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 1999 |
Control of SIV rebound through structured treatment interruptions during early infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Hydroxyurea; Lymphocyte Activation; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; Random Allocation; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Viremia; Virus Replication | 2000 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Stavudine; Zalcitabine; Zidovudine | 1996 |
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; Antigens, CD34; Cell Line; Didanosine; Dideoxynucleosides; Epithelial Cells; Hematopoietic Stem Cells; Humans; Kidney Tubules, Proximal; Liver; Muscle, Skeletal; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 2002 |
Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
Topics: Adenine; Cells, Cultured; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Enzyme Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Mycophenolic Acid; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Didanosine; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Synergism; Fatal Outcome; Humans; Male; Middle Aged; Mitochondria; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells.
Topics: Adenine; Anti-HIV Agents; Cells, Cultured; Chromatography, High Pressure Liquid; Culture Media; Didanosine; Drug Interactions; Humans; Leukocytes, Mononuclear; Organophosphonates; Organophosphorus Compounds; Phosphorylation; Tenofovir | 2003 |
Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Interactions; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Ritonavir; Stavudine; Tenofovir | 2003 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir | 2003 |
Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Topics: Adenine; Adult; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Tenofovir | 2003 |
Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Humans; Lopinavir; Male; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Ritonavir; Tenofovir | 2003 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.
Topics: Adenine; Allopurinol; Anti-HIV Agents; Antimetabolites; Antiviral Agents; Biotransformation; Caco-2 Cells; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; Enzyme Inhibitors; Ganciclovir; Humans; Intestinal Absorption; Kinetics; Organophosphonates; Organophosphorus Compounds; Permeability; Purine-Nucleoside Phosphorylase; Substrate Specificity; Tenofovir | 2004 |
French investigators warn of LPV/TDF/ddI interaction.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nucleosides; Nucleotides; Organophosphonates; Organophosphorus Compounds; Prevalence; Tenofovir | 2004 |
Tenofovir-related nephrotoxicity in HIV-infected patients.
Topics: Acute Kidney Injury; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Tenofovir | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2004 |
Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Area Under Curve; Comorbidity; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Topics: Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Pancreatitis; Tenofovir | 2004 |
Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nucleosides; Organophosphonates; Phenotype; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Genetic; Didanosine; DNA, Viral; Drug Resistance, Multiple, Viral; Gene Deletion; Genotype; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir | 2004 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Oxazines; Tenofovir; United States; United States Food and Drug Administration | 2004 |
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Topics: Adenine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Lymphopenia; Organophosphonates; Purine-Nucleoside Phosphorylase; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2004 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2005 |
Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Topics: Adenine; Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Synergism; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2005 |
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Organophosphonates; Retrospective Studies; Survival Rate; Tenofovir; Treatment Failure; Viral Load | 2005 |
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Female; HIV Infections; Humans; Lymphopenia; Male; Organophosphonates; Risk Factors; Tenofovir | 2005 |
High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2005 |
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
Should tenofovir ever be used in association with didanosine?
Topics: Adenine; Anti-HIV Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; HIV Infections; HIV-1; Humans; Longitudinal Studies; Organophosphonates; Oxidative Phosphorylation; Prospective Studies; Retrospective Studies; Tenofovir | 2006 |
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney; Male; Microscopy, Electron; Middle Aged; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; HIV Infections; Humans; Mitochondria; Organophosphonates; Purine-Nucleoside Phosphorylase; Tenofovir | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2006 |
Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Glucose; Didanosine; Drug Therapy, Combination; Fasting; Female; Follow-Up Studies; HIV Infections; Humans; Hyperglycemia; Linear Models; Male; Organophosphonates; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2006 |
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Arginine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lysine; Organophosphonates; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2006 |
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Organophosphonates; Purine-Nucleoside Phosphorylase; Tenofovir | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
Topics: Adenine; Didanosine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Genetic Variation; Genotype; HIV-1; Humans; Inhibitory Concentration 50; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Tenofovir; Time Factors | 2006 |
Hypokalemia in HIV patients on tenofovir.
Topics: Adenine; Adolescent; Adult; Body Weight; Child; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypokalemia; Kidney Diseases; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Tenofovir; Time Factors | 2006 |
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Interactions; Electron Transport Complex IV; Humans; Kidney Tubules, Proximal; Lopinavir; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; RNA; Tenofovir; Zidovudine | 2006 |
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Organophosphonates; Risk Factors; Sex Characteristics; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Hypersensitivity; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Carbamates; Creatinine; Didanosine; Drug Interactions; Female; Furans; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Linear Models; Male; Middle Aged; Organophosphonates; Sulfonamides; Tenofovir; Time Factors | 2007 |
Adverse events experienced by three children taking tenofovir and didanosine in combination.
Topics: Adenine; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2007 |
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2007 |
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Semen; Sperm Motility; Spermatozoa; Tenofovir | 2007 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Tenofovir renal toxicity targets mitochondria of renal proximal tubules.
Topics: Adenine; AIDS-Associated Nephropathy; Animals; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Female; HIV-1; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdissection; Mitochondria; Organophosphonates; Tenofovir; Urothelium | 2009 |
Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Topics: Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; Humans; Kidney Function Tests; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2009 |
Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Didanosine; Drug Administration Schedule; Drug Interactions; Fatal Outcome; HIV Infections; Humans; Immunocompromised Host; Lung Diseases, Fungal; Male; Middle Aged; Organophosphonates; Pancreatitis; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2009 |
Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats.
Topics: Adenine; Animals; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Electron Transport; Electron Transport Complex IV; Kidney Tubules, Proximal; Male; Microscopy, Electron, Transmission; Mitochondria; Mitochondrial Diseases; NADH Dehydrogenase; Organophosphonates; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Killer Cells, Natural; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; T-Lymphocytes; Tenofovir | 2009 |
Recent FDA approvals and changes.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Delayed-Action Preparations; Didanosine; Drug Approval; Drug Labeling; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2010 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Didanosine; Female; HIV Infections; Humans; Hyperplasia; Hypertension, Portal; Liver; Liver Regeneration; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2011 |
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Topics: Adenine; Anti-HIV Agents; Apoptosis; Cardiovascular Diseases; Cell Adhesion Molecules; Coronary Vessels; Cytokines; Didanosine; Dideoxynucleosides; Endothelial Cells; Gene Expression; Gene Expression Profiling; HIV Infections; HIV-1; Humans; Inflammation; NADPH Oxidases; Organophosphonates; Oxidative Stress; Primary Cell Culture; Proto-Oncogene Proteins; Tenofovir | 2011 |
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Portal; Liver; Male; Middle Aged; Multivariate Analysis; Netherlands; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Young Adult | 2012 |
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA Primers; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Telomerase; Tenofovir; Zidovudine | 2012 |
Comparative buccal permeability enhancement of didanosine and tenofovir by potential multifunctional polymeric excipients and their effects on porcine buccal histology.
Topics: Acrylic Resins; Adenine; Administration, Buccal; Alginates; Animals; Anti-HIV Agents; Carboxymethylcellulose Sodium; Didanosine; Excipients; Glucuronic Acid; Hexuronic Acids; Mouth Mucosa; Organophosphonates; Permeability; Polyethylene Glycols; Swine; Tenofovir | 2014 |